Genmab to buy cancer biotech Merus for $8B

Danish biotech Genmab plans to acquire Merus, a clinical-stage biotech developing an antibody for head and neck cancer, in a deal worth $8 billion.

Why it matters: Big-ticket biotech acquisitions are heating up following two others earlier this month.